메뉴 건너뛰기




Volumn 24, Issue 8, 2013, Pages 2119-2123

Central nervous system involvement in mantle cell lymphoma: Clinical features, prognostic factors and outcomes from the European mantle cell lymphoma network

(19)  Cheah, C Y a,l   George, A a   Gine E b   Chiappella, A c   Kluin Nelemans, H C d   Jurczak, W e   Krawczyk, K e   Mocikova, H f   Klener, P g   Salek, D h   Walewski, J i   Szymczyk, M i   Smolej, L j   Auer, R L k   Ritchie, D S a,l   Arcaini, L m,n   Williams, M E o   Dreyling, M p   Seymour, J F a,l  


Author keywords

Central nervous system; Mantle cell lymphoma; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

EID: 84881237232     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt139     Document Type: Article
Times cited : (93)

References (23)
  • 2
    • 27744523816 scopus 로고    scopus 로고
    • Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network
    • Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29-38.
    • (2005) Br J Haematol , vol.131 , pp. 29-38
    • Tiemann, M.1    Schrader, C.2    Klapper, W.3
  • 3
    • 34250196140 scopus 로고    scopus 로고
    • Leukemic involvement is a common feature in mantle cell lymphoma
    • Ferrer A, Salaverria I, Bosch F, et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007; 109: 2473-2480.
    • (2007) Cancer , vol.109 , pp. 2473-2480
    • Ferrer, A.1    Salaverria, I.2    Bosch, F.3
  • 4
    • 0036791667 scopus 로고    scopus 로고
    • Cerebrospinal fluid involvement in mantle cell lymphoma
    • Valdez R, Kroft SH, Ross CW, et al. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol 2002; 15: 1073-1079.
    • (2002) Mod Pathol , vol.15 , pp. 1073-1079
    • Valdez, R.1    Kroft, S.H.2    Ross, C.W.3
  • 5
    • 39049105188 scopus 로고    scopus 로고
    • Central nervous system involvement in mantle cell lymphoma
    • Ferrer A, Bosch F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135-141.
    • (2008) Ann Oncol , vol.19 , pp. 135-141
    • Ferrer, A.1    Bosch, F.2    Villamor, N.3
  • 6
    • 70349207134 scopus 로고    scopus 로고
    • Mantle cell lymphoma with central nervous system involvement: frequency and clinical features
    • Gill S, Herbert KE, Prince HM, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 2009; 147: 83-88.
    • (2009) Br J Haematol , vol.147 , pp. 83-88
    • Gill, S.1    Herbert, K.E.2    Prince, H.M.3
  • 7
    • 0033012454 scopus 로고    scopus 로고
    • Central nervous system involvement in patients with mantle cell lymphoma
    • Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999; 78: 145-149.
    • (1999) Ann Hematol , vol.78 , pp. 145-149
    • Oinonen, R.1    Franssila, K.2    Elonen, E.3
  • 9
    • 77951453410 scopus 로고    scopus 로고
    • Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
    • Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115: 3215-3223.
    • (2010) Blood , vol.115 , pp. 3215-3223
    • Pott, C.1    Hoster, E.2    Delfau-Larue, M.H.3
  • 10
    • 20144388941 scopus 로고    scopus 로고
    • Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
    • Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.
    • (2005) Blood , vol.105 , pp. 2677-2684
    • Dreyling, M.1    Lenz, G.2    Hoster, E.3
  • 11
    • 20144376591 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
    • Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
    • (2005) J Clin Oncol , vol.23 , pp. 1984-1992
    • Lenz, G.1    Dreyling, M.2    Hoster, E.3
  • 12
    • 33746605975 scopus 로고    scopus 로고
    • A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus
    • Gesk S, Klapper W, Martin-Subero JI, et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 2006; 108: 1109-1110.
    • (2006) Blood , vol.108 , pp. 1109-1110
    • Gesk, S.1    Klapper, W.2    Martin-Subero, J.I.3
  • 13
    • 33644786965 scopus 로고    scopus 로고
    • Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts longterm remission in mantle cell lymphoma
    • Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts longterm remission in mantle cell lymphoma. Blood 2006; 107: 2271-2278.
    • (2006) Blood , vol.107 , pp. 2271-2278
    • Pott, C.1    Schrader, C.2    Gesk, S.3
  • 14
    • 38349104577 scopus 로고    scopus 로고
    • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
    • Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
    • (2008) Blood , vol.111 , pp. 558-565
    • Hoster, E.1    Dreyling, M.2    Klapper, W.3
  • 15
    • 24644432553 scopus 로고    scopus 로고
    • Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
    • Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-5043.
    • (2005) J Clin Oncol , vol.23 , pp. 5034-5043
    • Abrey, L.E.1    Batchelor, T.T.2    Ferreri, A.J.3
  • 16
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 17
    • 49649088421 scopus 로고    scopus 로고
    • [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma
    • Gill S, Wolf M, Prince HM, et al. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008; 8: 159-165.
    • (2008) Clin Lymphoma Myeloma , vol.8 , pp. 159-165
    • Gill, S.1    Wolf, M.2    Prince, H.M.3
  • 18
    • 57449089000 scopus 로고    scopus 로고
    • What is the real risk of central nervous system involvement in mantle cell lymphoma?
    • Gill S, Seymour JF. What is the real risk of central nervous system involvement in mantle cell lymphoma?. Leuk Lymphoma 2008; 49: 2237-2239.
    • (2008) Leuk Lymphoma , vol.49 , pp. 2237-2239
    • Gill, S.1    Seymour, J.F.2
  • 19
    • 79251532085 scopus 로고    scopus 로고
    • Flow cytometric immunophenotyping of cerebrospinal fluid specimens
    • Craig FE, Ohori NP, Gorrill TS, et al. Flow cytometric immunophenotyping of cerebrospinal fluid specimens. Am J Clin Pathol 2011; 135: 22-34.
    • (2011) Am J Clin Pathol , vol.135 , pp. 22-34
    • Craig, F.E.1    Ohori, N.P.2    Gorrill, T.S.3
  • 20
    • 77956971692 scopus 로고    scopus 로고
    • Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
    • Sancho JM, Orfao A, Quijano S, et al. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol 2010; 85: 321-328.
    • (2010) Eur J Haematol , vol.85 , pp. 321-328
    • Sancho, J.M.1    Orfao, A.2    Quijano, S.3
  • 21
    • 19944428085 scopus 로고    scopus 로고
    • High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology
    • Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105: 496-502.
    • (2005) Blood , vol.105 , pp. 496-502
    • Hegde, U.1    Filie, A.2    Little, R.F.3
  • 22
    • 0036332548 scopus 로고    scopus 로고
    • Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediategrade non-Hodgkin's lymphoma
    • Chua SL, Seymour JF, Streater J, et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediategrade non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43: 1783-1788.
    • (2002) Leuk Lymphoma , vol.43 , pp. 1783-1788
    • Chua, S.L.1    Seymour, J.F.2    Streater, J.3
  • 23
    • 84859211271 scopus 로고    scopus 로고
    • CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?
    • Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?. Blood Rev 2012; 26: 97-106.
    • (2012) Blood Rev , vol.26 , pp. 97-106
    • Siegal, T.1    Goldschmidt, N.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.